alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 176 studies with an author at Yale University (US) (page 6 of 8) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 176 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2010-10-01

Severity of psychiatric symptoms, behavioral disturbances, and patients' quality of life are the main correlates of caregivers' experience burden. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of biological chemistry 2006-04-19

Recently, we have shown that green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) exerts a beneficial role on reducing brain Abeta levels, resulting in mitigation of cerebral amyloidosis in a mouse model of Alzheimer disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia Diagnosis Underreporting and Care Engagement and Planning Among Older Adults

✓ Peer-reviewed alzhub usefulness score 47 out of 100. JAMA Network Open 2026-08-26

Among 6158 person-waves with a claims-based dementia diagnosis from 3278 PWPD (3134 [50.9%] aged 65-84 years; 4282 [69.5%] female; 1176 [19.1%] non-Hispanic Black, 617 [10.0%] Hispanic, and 4256 [69.1%] non-Hispanic White), the adjusted proportion not reporting their diagnosis was 42% (95% CI, 40%-43%) among all respondents and 67% (95% CI, 64%-69%) among self-respondents. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Nuclear Medicine 2012-02-13

Florbetapir F 18 appears to have a wide effective dose range and a high test-retest reliability for both quantitative (SUVr) values and visual assessment of the ligand.

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 1994-05-01

Abnormal metabolic processing of the beta/A4 amyloid precursor protein (APP) has been implicated in the pathogenesis of Alzheimer disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Journal of biological chemistry 2015-05-27

Alzheimer disease (AD) is characterized by amyloid-β accumulation, with soluble oligomers (Aβo) being the most synaptotoxic. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biological psychiatry 2017-10-14

Recent genetic studies have provided overwhelming evidence of the involvement of microglia-related molecular networks in the pathophysiology of Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk Adjustment for Alzheimer Disease and Related Dementias in Medicare Advantage and Health Care Experiences

✓ Peer-reviewed alzhub usefulness score 46 out of 100. JAMA Network Open 2026-03-13

Among 5353 MA beneficiary observations (1239 [23.1%] aged 65-74 years; 3127 [58.4%] aged ≥75 years; 1785 male [33.3%]), 1629 (30.4%) reported a diagnosis of ADRD, and 3724 (69.6%) did not report an ADRD diagnosis. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson’s disease and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Nature Communications 2025-09-26

GBA is the major risk gene for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), two common α-synucleinopathies with cognitive deficits. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of biological chemistry 2011-01-07

Individuals with Down syndrome (DS) will inevitably develop Alzheimer disease (AD) neuropathology sometime after middle age, which may be attributable to genes triplicated in individuals with DS. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2007-12-21

As different signature changes associated with particular stages of disease burden are identified and validated, we anticipate expanded application of qEEG as a reliable and sensitive biomarker(s) of MCI and early Alzheimer's disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effects of Normative Adjustments to the Montreal Cognitive Assessment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2018-09-21

499 adults 48 to 91 years-old enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and were administered the MoCA during baseline. 4 key findings →

Participants: 499 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intra-individual variability in Alzheimer's disease and cognitive aging: definitions, context, and effect sizes

✓ Peer-reviewed alzhub usefulness score 45 out of 100. PloS one 2011-04-19

Sample statistics were computed from ADNI cohorts with no cognitive diagnosis, a diagnosis of mild cognitive impairment (MCI), and a diagnosis of possible or probable Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Geospatial analysis of patients’ social determinants of health for health systems science and disparity research

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Anesthesiology Clinics 2022-12-08

The cross-disciplinary expertise, required for GA, common in the days before medical specialization and enabled by the relative paucity of development in various fields compared with today, can be reborn with the advent of Electronic Health Records (EHR) systems that make the tools of medical geography accessible to a wide variety of health care researchers and clinical subspecialties. 4 key findings →

Participants: 127 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluating The Accuracy Of Medicare Risk Adjustment For Alzheimer’s Disease And Related Dementias

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Health Affairs 2022-09-01

In 2020 Medicare reintroduced Alzheimer's disease and related dementias (ADRD) Hierarchical Condition Categories (HCCs) to risk-adjust Medicare Advantage and accountable care organization (ACO) payments. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Neighborhood‐Level Disadvantage with Cerebrovascular Disease Neuropathology in a National Sample of Brain Donors

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-12-01

We found that ∼25% of donors lived in high deprivation contexts, 52% had at least one incidence of CVD, and the cohort identified as .05). 3 key findings →

Participants: 7,187 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer disease and associated disorders 2025-01-13

Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive. 4 key findings →

Design: cohort study Participants: 61 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed